Shanxi Zhendong Pharmaceutical Co., Ltd. Class A

Shanxi Zhendong Pharmaceutical Co., Ltd. Class A

SSZSE:300158
4.49
CNY
-0.11
(-2.39%)
-1.37EPS
4.42BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
2.88
3.33
3.93
4.49
7.22
3.3
4.28
4.72
4.96
3.63
3.53
2.9
- -
- -
Basic EPS, GAAP
0.13
0.07
0.11
0.28
0.58
-0.14
0.14
0.26
2.55
-0.05
-0.04
-1.3
- -
- -
Free Cash Flow per Basic Share
-0.54
-0.12
0.18
-0.26
-0.01
0.13
0.16
0.04
0.13
-0.06
-0.36
-0.44
- -
- -
Dividend per Share
0.06
0.09
0.15
0.27
0.1
0.05
0.02
0.08
0.19
2.71
- -
- -
- -
- -
Book Value per Share
3.38
3.4
3.46
5.05
5.33
5.13
5.26
5.49
7.86
5.11
5.04
3.68
- -
- -
Tangible Book Value per Share
2.53
2.54
2.55
2.28
2.55
2.47
2.6
2.86
7.4
4.64
4.56
3.29
- -
- -
Basic Weighted Avg Shares
576
576
576
731
517
1,035
1,028
1,028
1,027
1,028
1,028
1,024
1,004
988
Sales/Revenue/Turnover
1,658
1,919
2,262
3,283
3,732
3,420
4,399
4,848
5,094
3,729
3,626
2,971
- -
- -
Operating Margin (%)
6.94
3.16
4.89
8.27
12.19
3.09
5.97
7.33
4.13
-2.75
-1.82
-11.4
- -
- -
Depreciation Expense
43
74
82
114
110
114
116
166
125
126
122
115
- -
- -
Net Income, GAAP
74
42
65
203
302
-147
143
262
2,617
-51
-44
-1,329
- -
- -
Effective Tax Rate (%)
28.6
29.49
19.77
17.18
19.34
- -
28.41
21.46
16.25
- -
- -
- -
- -
- -
Profit Margin (%)
4.46
2.19
2.86
6.19
8.08
-4.31
3.25
5.41
51.38
-1.38
-1.21
-44.72
- -
- -
Working Capital
569
524
-127
1,478
1,721
1,696
1,866
2,111
6,623
3,674
3,543
1,961
- -
- -
LT Debt
21
25
60
39
200
292
284
20
101
1
2
1
- -
- -
Total Equity
1,958
1,970
2,030
5,272
5,558
5,300
5,441
5,625
8,054
5,223
5,144
3,660
- -
- -
Return on Invested Capital (%)
2.63
0.72
1.38
4.13
4.93
- -
2.38
4.47
36.17
- -
- -
- -
- -
- -
Return on Capital (%)
3.87
2.92
3.13
5.15
5.3
- -
2.84
4.84
36.62
- -
- -
- -
- -
- -
Return on Common Equity (%)
3.87
2.15
3.27
5.61
5.59
-2.72
2.66
4.73
38.17
-0.77
-0.84
-29.93
- -
- -

Capital Structure

CNY

•

in mil. unless spec.
Mar'25
Jun'25
Dec'25
ST Debt
16
2
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
1
1
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,005
1,005
991
Market Capitalization
4,011
4,423
5,761

Working Capital

CNY

•

in mil. unless spec.
Mar'25
Jun'25
Dec'25
Total Current Assets
2,858
2,683
- -
Cash, Cash Equivalents & STI
1,174
1,030
- -
Accounts Receivable, Net
667
733
- -
Inventories
643
637
- -
Total Current Liabilities
945
842
- -
Payables & Accruals
- -
- -
- -
ST Debt
16
2
- -
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
- -
Free Cash Flow
- -
- -
- -
Net Income, GAAP
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
782
724
763
702
2,971
2025
755
702
- -
- -
- -
2026
- -
447
436
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.02
0.01
0.01
-1.36
-1.3
2025
- -
0.01
- -
- -
- -
2026
- -
-0.09
-0.08
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
Yong Hua Chen
Full Time Employees
3,695
Sector
Health technology
Industry
Pharmaceuticals: other
Address
Zhendong Science and Technology Park Changzhi SX China 047100
IPO Date
Dec 24, 2010
Website
zdjt.com
Business
Shanxi Zhendong Pharmaceutical Co.,Ltd, alongside its affiliated entities, focuses on the research, development, production, and commercialization of a wide array of pharmaceutical products and traditional Chinese medicines across China. The company develops both innovative and generic medications, addressing therapeutic areas such as oncology, cardiovascular health, dermatological conditions, digestive disorders, urology, and infectious diseases. Beyond conventional pharmaceuticals and Chinese herbal formulations, Shanxi Zhendong has broadened its portfolio to include active pharmaceutical ingredients, functional foods, and home care items. The firm actively manages a complete traditional Chinese medicine supply chain, encompassing everything from cultivation to processing. Recent activities include advancing Phase IIa clinical trials for its Class 1.1 traditional Chinese medicine, Xinglou Chengqi Granules, designed to address phlegm and promote bowel movements, with initial patient enrollment occurring in November 2025. The company's product offerings are delivered in diverse formats. Shanxi Zhendong Pharmaceutical Co.,Ltd maintains its primary operations in Changzhi, China.